Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $417.2 million.

  • UNITED THERAPEUTICS's Cash from Investing Activities rose 222.63% to $140.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$446.9 million, marking a year-over-year decrease of 176.72%. This contributed to the annual value of $417.2 million for FY2024, which is 157.98% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Cash from Investing Activities stood at $417.2 million for FY2024, which was up 157.98% from -$719.6 million recorded in FY2023.
  • UNITED THERAPEUTICS's 5-year Cash from Investing Activities high stood at $417.2 million for FY2024, and its period low was -$811.5 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$371.3 million, with a median of -$719.6 million in 2023.
  • In the last 5 years, UNITED THERAPEUTICS's Cash from Investing Activities tumbled by 120.18% in 2020 and then soared by 157.98% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash from Investing Activities (MRY) stood at -$738.5 million in 2020, then soared by 34.07% to -$486.9 million in 2021, then crashed by 66.67% to -$811.5 million in 2022, then increased by 11.32% to -$719.6 million in 2023, then skyrocketed by 157.98% to $417.2 million in 2024.
  • Its Cash from Investing Activities was $417.2 million in FY2024, compared to -$719.6 million in FY2023 and -$811.5 million in FY2022.